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ABSTRACT
We have studied the mutagenic properties of
ribonucleotide analogues by reverse trans-
cription to understand their potential as antiretro-
viral agents by mutagenesis of the viral genome.
The templating properties of nucleotide analogues
including 6-(b-D-ribofuranosyl)-3,4-dihydro-8H-
pyrimido[4,5-c](1,2)oxazin-7-one, N
4-hydroxycytidine,
N
4-methoxycytidine, N
4-methylcytidine and
4-semicarbazidocytidine, which have been reported
to exhibit ambiguous base pairing properties, were
examined. We have synthesized RNA templates
using T3 RNA polymerase, and investigated the
specificity of the incorporation of deoxyribo-
nucleoside triphosphates opposite these cytidine
analogues in RNA by HIV and AMV reverse trans-
criptases. Except for N
4-methylcytidine, both
enzymes incorporated both dAMP and dGMP oppo-
site these analogues in RNA. This indicates that
they would be highly mutagenic if present in
viral RNA. To study the basis of the differences
among the analogues in the incorporation ratios
of dAMP to dGMP, we have carried out kinetic
analysis of incorporation opposite the analogues
at a defined position in RNA templates. In addition,
we examined whether the triphosphates of these
analogues were incorporated competitively into
RNA by human RNA polymerase II. Our present
data supports the view that these cytidine ana-
logues are mutagenic when incorporated into
RNA, and that they may therefore be considered as
candidates for antiviral agents by causing mutations
to the retroviral genome.
INTRODUCTION
Genetic diversities of retroviruses and RNA viruses caused
by their higher mutation rates allow the viral population to
escape host immune responses, resulting in rapid antiviral
drug resistance (1,2). The higher mutation rates may result
in many defective virions, because deleterious mutations in
essential genes should also take place (2). Thus, it has been
suggested that these viruses exist near their ‘error thresholds’,
maximal mutation rates to sustain production of infectious
progenies (3). Induction of mutations exceeding these thresh-
olds could lead these viruses to extinction, which is termed
error catastrophe or lethal mutagenesis (4–7). Among the
various types of mutagen, nucleotide analogues, which do
not incorporate into DNA, may be suitable for this purpose.
Therefore, it is important to explore the use of such analogues
for their potential to serve as novel antiviral agents. Indeed, it
has been suggested that ribavirin, a broad-spectrum antiviral
ribonucleoside, forces poliovirus and hantavirus into error
catastrophe (4,8,9). A small increase in the mutation fre-
quency by 5-azacytidine or 5-ﬂuorouracil causes dramatic
reduction in the survival levels of poliovirus, vesicular sto-
matitis virus, foot-and-mouth disease virus and lymphocytic
choriomeningitis virus (10–13). In retroviruses, experiments
with 5-hydroxy-20-deoxycytidine (5-OH-dC) and 5-aza-5,
6-dihydro-20-deoxycytidine (KP-1212) it has been demon-
strated that it is possible to increase mutation rates and
eradicate HIV by repeated passages in the presence of these
deoxyribonucleoside analogues (6,14). However, deoxyri-
bonucleoside analogues may also be incorporated into host
genomic DNA, and mutations in the host genome may be
induced. Unlike deoxynucleosides, ribonucleoside analogues
are not directly incorporated into the host genomic DNA.
Ribonucleoside analogues can be incorporated into cellular
RNA resulting in altered proteins. However, it will be a
transient aberration, because mRNAs have short half-lives
and proteins tolerate a wide variety of mutations (15–19).
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in error catastrophe than deoxynucleosides (20). We have
studied the mutagenic properties of several ribonucleotide
triphosphate analogues using a reverse transcription assay
to determine their mutagenic potential; mutagenic analogues
can be considered as potential antiretroviral agents by
inducing mutations to the viral genome, which in turn leads
to lethal mutagenesis.
6-(b-D-ribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c](1,2)
oxazin-7-one triphosphate (rPTP) has been shown to induce
U-to-C and C-to-U transition mutations in an in vitro
retroviral replication model using phage T3 RNA polymerase
and AMV reverse transcriptase (21). It was reported that
the triphosphates of N
4-hydroxycytidine (ho
4C), N
4-methoxy-
cytidine (mo
4C) and N
4-methylcytidine (m
4C) exhibited
ambiguous properties in polymerization (22–24), and
N
4-aminodeoxycytidine triphosphate can be incorporated in
place of both dCTP and dTTP (25,26). We have found that
4-semicarbazidocytidine triphosphate, a N
4-aminocytidine
derivative, can be incorporated as UTP by phage RNA poly-
merase (27) (Figure 1). These N
4-cytidine analogues except
m
4C show ambiguous base pairing properties by amino-
imino tautomerism; the presence of the electronegative
element on the N
4-amino group reduces their tautomeric
constants close to unity (28,29). In the present study, we
have investigated the speciﬁcity of incorporation of deoxyri-
bonucleoside triphosphates opposite these cytidine analogues
in RNA by HIV and AMV reverse transcriptases. Except
m
4C, HIV and AMV reverse transcriptases incorporated
both dAMP and dGMP opposite these analogues when
present in RNA. This indicates that these substrates would
be highly mutagenic if present in the viral RNA. To study
the basis of the differences among the analogues in the
incorporation ratios of dAMP to dGMP, we have measured
the kinetics of incorporation of dNTPs opposite the analogues
at deﬁned positions in RNA templates using a primer exten-
sion protocol. In addition, we have examined whether the
triphosphates of these analogues were incorporated competi-
tively into RNA by human RNA polymerase II.
MATERIALS AND METHODS
Materials
Recombinant HIV reverse transcriptase was expressed
in Escherichia coli by using plasmid p6HRT-PROT kindly
provided by Dr S. F. Le Grice of National Institutes of
Health (30), and puriﬁed by Ni-NTA agarose (QIAGEN).
AMV reverse transcriptase, Tﬂ DNA polymerase, T3 RNA
polymerase, HeLa nuclear extract and calf intestinal alkaline
phosphatase were purchased from Promega (Madison, WI).
Synthesis of ribonucleoside analogues
N
4-Hydroxycytidine 50-triphosphate
N
4-Hydroxycytidine 50-triphosphate was prepared as descri-
bed previously (31) with a slight modiﬁcation. Brieﬂy, CTP
(30 mg) was treated in 0.2 ml of 2 M hydroxylamine
hydrochloride (pH 5.0) at 55 C for 5 h. The samples of
ho
4CTP were puriﬁed by reverse phase high-performance
liquid chromatography (HPLC) using an ODS-120A
(TOSOH) column eluted with 3% methanol-10 mM tri-
ethylammonium bicarbonate (pH 6.8), at 0.7 ml/min. The
samples were further puriﬁed by anion exchange HPLC
using a DEAE-2sw (TOSOH) column [0.06 M disodium
Figure 1. Structure of N
4-modified cytidine analogues used in this study.
Nucleic Acids Research, 2006, Vol. 34, No. 22 6439hydrogenphosphate-20% acetonitrile (pH 6.6) and 0.7 ml/min]
and then puriﬁed by reverse phase HPLC again as described
above.
N
4-Methoxycytidine 50-triphosphate
N
4-Methoxycytidine 50-triphosphate was prepared as des-
cribed previously (23), and puriﬁed by three-step HPLC as
ho
4CTP.
N
4-Methylcytidine 50-triphosphate
N
4-Methylcytidine 50-triphosphate was prepared by bisulﬁte-
catalyzed transamination of CTP (32). CTP (25 mg) was
mixed with a 0.25 ml solution containing 4 M monomethy-
lamine, 0.4 M sodium bisulﬁte and 0.1 M sodium dihydro-
genphosphate (pH 7.5) and reacted at 60 C for 2 days.
The samples of m
4CTP were puriﬁed by HPLC as described
for ho
4CTP.
4-Semicarbazidocytidine 50-triphosphate
4-Semicarbazidocytidine 50-triphosphate was prepared
according to the method described for 4-semicarbazi-
docytidine (33) with a slight modiﬁcation. CTP (15 mg)
was reacted in a solution (0.1 ml) containing 1 M semicar-
bazide hydrochloride and 0.5 M sodium bisulﬁte (pH 5.4)
at room temperature for 4 h. To this solution was added
4 ml of 0.5 M sodium phosphate (pH 6.5) and 1.8 ml of
water and the reaction kept at 37 C for 2 h. The crude
sc
4CTP sample was diluted by addition of 80 ml water,
loaded on to a DE52 column (2 · 9 cm), which was washed
with 50 ml of 25 mM sodium phosphate (pH 7) and 50 ml of
25 mM sodium phosphate (pH 7) supplemented with 7 M
urea. The triphosphate was eluted in a gradient from
0.025 mM to 0.4 M sodium phosphate (pH 7), containing
7 M urea. The sample was loaded onto another DE52 column
(1.4 · 3 cm), and washed with 50 ml of 0.05 M ammon-
ium bicarbonate. sc
4CTP eluting in with 1 M ammonium
bicarbonate. The sample was further puriﬁed by reverse
phase HPLC using an ODS-120A (TOSOH) column [3%
methanol-10 mM triethylammonium bicarbonate (pH 6.8)
and 0.7 ml/min].
Synthesis of the nucleosides and nucleotides, and
confirmation of the modified triphosphates
Modiﬁed ribonucleosides, ho
4C, mo
4C, sc
4C and m
4C, and
their 20/30-monophosphates were prepared with cytidine
and 20/30-CMP, respectively, in an analogous reaction as
used for the preparation of triphosphates. ho
4C, m
4C, mo
4C
and sc
4C were shown to be >98% pure in two HPLC systems,
and veriﬁed by
1H-NMR and mass spectrometry. The
nucleosides were shown to be co-eluted in two HPLC
systems with the nucleosides obtained by digestion of
triphosphate analogues. For the preparation of its 20/30-
monophosphate, RNA containing rP synthesized as below
was digested with RNase T2, and puriﬁed by HPLC. All
the triphosphates and monophosphates showed the same
ultraviolet (UV) absorbance as the nucleosides at acidic,
neutral and basic pHs.
6-(b-D-Ribofuranosyl)-3,4-dihydro-8H-pyrimido
[4,5-c](1,2)oxazin-7-one 50-triphosphate (rPTP)
6-(b-D-Ribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c](1,2)
oxazin-7-one, and its 50-triphosphate were prepared as
described previously (34).
Transcription by T3 RNA polymerase
The DNA fragment of pBluescript II SK ( ) digested by
BssHII puriﬁed on agarose gel were used as a template to
produce 155 nt runoff transcripts from T3 promoter. Standard
transcription reaction mixtures (20 ml) contained 40 mM
Tris–HCl (pH 7.4), 6 mM MgCl2, 2 mM spermidine,
10 mM NaCl, 10 mM DTT, 0.5 mM rNTPs, 50 ng DNA
template, 20 U RNase inhibitor (Wako, Osaka, Japan), and
10 U T3 RNA polymerase. The mixtures were incubated at
37 C for 1 h. For the incorporation of the cytidine analogues,
they were added in place of one of four normal nucleotides
in an equal or 10-fold excess concentration of the normal
nucleotides. After the transcription, the DNA template was
degraded by incubation at 37 C for 30 min with 2 U DNaseI.
The reactions were monitored by 7 M urea 8% denaturing
PAGE. The reactions were terminated with 1/10 volume
of 20 mM EGTA, deproteinated with phenol/chloroform/
isoamyl alcohol (25:24:1) and desalted by Centri-Sep spin
column. These RNA transcripts were used as templates for
reverse transcription (Figure 2).
Analysis of base composition
The HPLC analysis of RNA transcripts was performed
as described previously (35) with slight modiﬁcation. The
dried transcripts were dissolved in digestion mixtures
(30 ml) containing 50 mM Tris–HCl (pH 7.4), 10 mM
MgCl2 and 0.4 U snake venom phosphodiesterase I. The
mixtures were incubated at 37 C for 90 min. Subsequently,
0.2 U snake venom phosphodiesterase I and 2 U calf intesti-
nal alkaline phosphatase were added to the reactions, and
then incubation was continued at 37 C for 2 h. After the
digestion, non-digested materials were removed by ethanol
precipitation. The supernatants were dried by a SpeedVac,
and then dissolved in 20 ml buffer A [100 mM potassium
phosphate (pH 7.0)]. The nucleosides were separated by
reverse phase HPLC with ODS column (ultrasphere ODS,
BECKMAN) eluting at a ﬂow rate of 0.7 ml/min using
sequential gradients of buffers A and B: 0–5 min 0%
B. 5–20 min 0–15% B. 20–35 min 15–45% B. 35–60 min
  
 
Figure 2. Sequence of RNA template and primer binding site. RNA templates
contain ho
4C, mo
4C, rP or sc
4C in place of U, and m
4C in place of C.
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sium phosphate (pH 7.0) and 90% methanol]. The concentra-
tion of each nucleoside was determined by monitoring A260
and integration using D-2500 Chromato-Integrator (Hitachi).
To conﬁrm the analogue peak, the digested products and each
nucleoside analogue were co-eluted by HPLC.
Reverse transcription with HIV RT
Reverse transcription reaction by HIV reverse transcriptase
was performed using RNA templates containing ho
4C,
mo
4C, rP, sc
4Co rm
4C. The heteroduplex template/primer
was prepared by heating a 1:1 (100 nM) mixture of DNA
primer 1 (50-CGAATTGGGTACCGGGCCCC-30) and RNA
template in a buffer (5 ml) containing 50 mM Tris–HCl
(pH 8.3), 50 mM KCl and 1% Nonidet P-40 at 70 C for
10 min, and cooling it slowly to room temperature. A reverse
transcription reaction mixture (10 ml) containing 50 mM
Tris–HCl (pH 8.3), 50 mM KCl, 1% Nonidet P-40, 10 mM
MgCl2, 3 mM DTT, 0.5 mM dNTPs, 50 nM template/primer,
5 U RNase inhibitor and 2 mM HIV reverse transcriptase was
incubated at 37 C for 1 h and then heated at 70 C for 10 min.
After the reaction, the RT products were ampliﬁed by
PCR. The PCR mixture (20 ml), which contained 10 mM
Tris–HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
dNTPs, 1 mM DNA primer 1, 1 mM DNA primer 2
(50-AAAGCTGGAGCTCCACCGCG-30), 1 ml RT products
and 0.5 U Taq DNA polymerase, was reacted by sequential
PCR program: 94 C 2 min [94 C3 0s ,5 5  C 1 min, 72 C
2 min] · 15 cycle. PCR roducts were puriﬁed on 2% agarose
gel, and a part of the puriﬁed DNA was sequenced directly
using a BigDye terminator v3.1 Cycle Sequencing Kit and
an ABI PRISM 3100-Avant Genetic Analyzer (Applied
Biosystems). The remaining cDNA was ligated into pBlue-
script II SK ( ) after digestion by SacI and KpnI, and cloned
in E.coli, and the integrated plasmid obtained from the
bacteria were sequenced with ABI PRISM 3100-Avant
Genetic Analyzer.
Reverse transcription with AMV RT
Reverse transcription reaction was also performed by AMV
reverse transcriptase using RNA templates, which contained
ho
4C, mo
4C, rP or sc
4C in place of U, and m
4C in place of
C. RT–PCR mixtures (20 ml) contained 1· AMV/Tﬂ buffer
(Promega), 1 mM MgSO4, 0.2 mM dNTPs, 1 mM DNA
primer 1, 1 mM DNA primer 2, 2.5 nM RNA template, 1 U
AMV reverse transcriptase and 1 U Tﬂ DNA polymerase.
The mixtures were reacted by sequential RT–PCR program:
48 C 45 min, 94 C 2 min, [94 C3 0s ,6 0  C 1 min and
68 C 2 min] · 15 cycle. Then, the RT–PCR products were
puriﬁed on 2% agarose gel and a part of the puriﬁed DNA
was sequenced directly using a BigDye terminator v3.1
Cycle Sequencing Kit and an ABI PRISM 3100-Avant
Genetic Analyzer (Applied Biosystems). The other cDNA
was ligated into pBluescript II SK ( ) after digestion by
SacI and KpnI, cloned in E.coli, and sequenced with an
ABI PRISM 3100-Avant Genetic Analyzer.
Steady-state kinetics
One base insertion reaction by HIV reverse transcriptase was
performed using RNA templates containing ho
4C, mo
4C, rP
or sc
4C in place of U. In a buffer containing 50 mM
Tris–HCl (pH 8.3), 50 mM KCl, 1% Nonidet P-40, 10 mM
MgCl2 and 3 mM DTT,
32P-labelled DNA primer (50 nM)
was annealed to the RNA template (75 nM) by heating at
90 C for 3 min and cooling slowly to room temperature.
Ins-primer (50-CCGGGCCCCCCCTCG-30) was used for
one base insertion opposite each analogue. ExtA-primer (50-
CCGGGCCCCCCCTCGA-30) and ExtG-primer (50-CCGG-
GCCCCCCCTCGG-30) were used for extension from dA
and dG, respectively, paired with the analogues. To the
template-primer (7 ml), 50 nM HIV RT (1 ml) was added
and pre-incubated at 37 C for 5 min. Each reaction was
initiated by addition of 2 mlo f5 · dNTP, and terminated
by addition of 10 ml of loading buffer [90% formamide,
0.05% BPB and 50 mM EDTA (pH 8.0)]. The reaction
products were analyzed by 7 M urea 20% denaturing
PAGE. The gels were exposed to Imaging Plate and analyzed
with Imaging Analyzer BAS-1800II (Fujiﬁlm) to quantitate
each band. The velocity of reaction was determined using
the following equation: vrel ¼ 100 I1 /( I0 + 0.5 I1) t, where
I0 is intensity of the unextended band, I1 is intensity of the
extended band and t is reaction time (36). The reaction
time was chosen to be in the linear range. Graphs of rate
versus dNTP concentration were analyzed using non-linear
regression in KaleidaGraph 4.0 for the determination of
Michaelis constant (Km) and relative maximum velocity
(Vmax, rel). The frequency values of insertion (fins) and
extension (fext) were deﬁned by a ratio of Vmax, rel/Km for
each base pair to Vmax, rel/Km for dA:U pair.
Transcription by human RNA polymerase II
and the nearest-neighbor analysis
RNA transcription by human RNA polymerase II was
performed using HeLa Nuclear Extract (Promega). A PCR
product (1140 bp) containing CMV immediate early
promoter and supF gene ampliﬁed from pCMV-supF plasmid
was used as a template for runoff transcription. A standard
reaction mixture (25 ml) contained 20 mM HEPES (pH
7.9), 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 3 mM
MgCl2, 0.4 mM ATP, CTP and UTP, 0.016 mM GTP,
450 ng DNA template, 40 U RNase inhibitor, 10 mCi
[a-
32P]GTP (3000 Ci/mmol) and 8 U HeLa nuclear extract.
To study incorporation of the ribonucleoside triphosphate
analogues, they were added in place of CTP or UTP. The
mixtures were incubated at 30 C for 1 h. The transcripts
were deproteinated with phenol/chloroform/isoamyl alcohol
(25:24:1) extraction and puriﬁed with Centri-Sep spin
column. The transcripts were separated by 7 M urea 5%
denaturing polyacrylamide gel, and analyzed with Imaging
Analyzer BAS-1800II (Fujiﬁlm).
For the nearest-neighbor analysis, the RNA transcripts
were digested in 10 ml of 15 mM sodium acetate (pH 4.5),
1.5% glycerol and 1 U RNase T2 at 37 C for 14 h. To
the dried reaction mixtures, 0.25 A260 U of non-isotopic 20,
30-NMPs were added as standards, and the digests were
analyzed by two-dimensional cellulose TLC (Funacel SF
10 · 10 cm) with the use of isobutyric acid/ammonia/water
(66:1:33, v./v./v.) for the ﬁrst dimension, and ammonium
sulfate/0.1 M sodium phosphate (pH 6.8)/n-propanol
(60:100:2, wt./v./v.) for the second dimension. The TLC
Nucleic Acids Research, 2006, Vol. 34, No. 22 6441plates were analyzed with Imaging Analyzer BAS-1800II
(Fujiﬁlm).
RESULTS
Incorporation of ribonucleotide analogues
in transcription by T3 RNA polymerase
Incorporation of the 50-triphosphates of the N
4-modiﬁed
cytidine analogues, ho
4C, mo
4C, m
4C, rP and sc
4C, into
RNA by T3 RNA polymerase was examined. Transcription
was performed using reaction mixtures where one of the
four triphosphates was replaced by an analogue. RNA tran-
scripts were produced when ho
4CTP and mo
4CTP were
used in place of UTP, and when m
4CTP was used in place
of CTP. Other combinations, e.g. ho
4CTP used in place of
CTP, GTP or ATP, produced no RNA transcripts even if
10-fold excess concentration was added (data not shown).
rPTP and sc
4CTP were incorporated into the transcripts as
a substitute of UTP as well as CTP (Supplementary
Figure S2). HPLC analysis demonstrated that almost all
uridine or cytidine in RNA was replaced by the analogues
in transcription by T3 RNA polymerase as shown in
Supplementary Table S1 and Supplementary Figure S3.
These transcripts were then used as templates for reverse
transcription. In addition to these cytidine analogues,
the incorporation of the 50-triphosphates of 3, N
4-ethenocyti-
dine, 9-(b-D-ribofuranosyl)-N
6-methoxy-2,6-diaminopurine,
2-hydroxyadenosine, inosine and 8-bromoadenosine were
studied, but these were not incorporated in place of any
normal nucleotides in this assay (data not shown).
Templating properties of mutagenic cytidine analogues
by reverse transcription
The RNA templates containing the N
4-modiﬁed cytidine ana-
logues were reverse-transcribed with HIV and AMV reverse
transcriptases to produce cDNAs, which were ampliﬁed by
PCR. The incorporation of native dNTPs opposite the ana-
logues was examined by direct sequencing of the ampliﬁed
cDNAs. In the direct sequencing electropherograms of the
cDNA produced with HIV reverse transcriptase, every peak
consists of a single line when the RNA template containing
only natural nucleotides was used. However, C peaks accom-
pany T peaks when the RNA templates contained ho
4C,
mo
4C, rP or sc
4C in place of U (Supplementary Figure
S4a). From the RNA containing the various substrates, the
average peak height ratios of C to T were 0.60 ± 0.06,
0.48 ± 0.03, 0.21 ± 0.02 and 7.2 ± 0.4 for cDNAs from
ho
4C-RNA, mo
4C-RNA, rP-RNA and sc
4C-RNA, respec-
tively. AMV reverse transcriptase gave similar results
(Supplementary Figure S4b). The average ratios of C peak
height to T peak height were 0.75 ± 0.04, 0.43 ± 0.03, 0.27
± 0.04 and 4.0 ± 0.5 for cDNAs from ho
4C-RNA,
mo
4C-RNA, rP-RNA and sc
4C-RNA, respectively. These
ratios correspond to those of incorporated nucleotides oppo-
site the analogues (data not shown). The mixed patterns in
the electropherograms indicated that these analogues in
RNA are mutagenic, causing ambiguous misincorporation
by HIV and AMV reverse transcriptases. The RNA template
containing m
4C exhibited no such ambiguity.
Sequencing analyses after cloning (Figure 3 and Supple-
mentary Table S2) gave similar results. The ratio of incor-
porated dGMP to dAMP opposite ho
4C and rP was 0.57
and 0.15 for HIV reverse transcriptase and 1.4 and 0.17 for
AMV reverse transcriptase, respectively. The G/A ratio for
mo
4C was approximately 0.35 for both reverse transcriptases.
The G/A ratio for sc
4C was 10.7 and 4.8 for HIV and AMV
reverse transcriptase, respectively. Therefore, these analogues
in RNA have the potential for inducing mutations at differ-
ent rates. In contrast, dGMP was preferentially incorporated
opposite m
4C by both reverse transcriptases consistent with
the results of the sequencing analyses on the cDNA without
cloning.
Steady-state kinetics of insertion opposite
ribonucleotide analogues by HIV RT
To study the ambiguous incorporation opposite the analogues
by HIV and AMV reverse transcriptases, the same template
was annealed to a primer to initiate incorporation of dNTPs
opposite the analogues (Figure 2 and Supplementary Figure
S1). Figure 4 shows typical patterns of the primer extension.
The steady-state Vmax and Km for the insertion of all four
natural dNTPs opposite the N
4-modiﬁed cytidine analogues
in RNA template were determined. As a control reaction,
the Vmax and Km for the RNA template containing uridine
at the same position were measured. The observed values
of kinetic data for each reaction are shown in Table 1. The
Km for the incorporation of dA opposite U is about the
same as a reported one (37). Among them, ho
4C, mo
4C and
rP are shown to be highly ambiguous in their base pairing
properties, consistent with the aforementioned sequencing
analyses. However, ho
4C and mo
4C are different from rP in
the mechanism that makes them mutagenic because ho
4C
and mo
4C can adopt either syn or anti conformers, whilst
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Figure 3. Rates of dATP and dGTP incorporated opposite cytidine analogues
by HIV RT (A) and AMV RT (B). Incorporated dATP and dGTP were
calculated from sequencing results of cloned cDNA. In this figure, averages
and standard deviations were calculated from three independent experiments.
6442 Nucleic Acids Research, 2006, Vol. 34, No. 22rP is constrained in the anti conformation. In the syn
conformation, the hydroxyl or methoxyl group protrudes
into the hydrogen bonding face.
The fins values of dGTP opposite ho
4C and mo
4C were
about the same as insertion of dGTP opposite U. However,
the values of dATP insertion opposite ho
4C and mo
4C were
20 and 42-fold smaller than opposite U, respectively. Thus,
the insertion ratio of dGTP to dATP opposite ho
4C and
mo
4C were about 50-fold higher than opposite U. In contrast,
the fins value of dGTP opposite rP was 18-fold higher
than opposite U, but the value of dATP was only 2-fold
higher than opposite U. Therefore, the insertion ratio of dGTP
to dATP opposite rP was 10-fold higher than opposite U.
Steady-state kinetics of extension of ribonucleotide
analogues pair by HIV RT
The other important factor to affect the yields of the mutated
cDNA is the efﬁciency of extension from the nucleotides
incorporated opposite the analogues. For this purpose,
Figure 4. Time course of insertion of dATP and dGTP opposite cytidine analogues. p: primer only.
Nucleic Acids Research, 2006, Vol. 34, No. 22 6443primers longer by 1 nt than those for the insertion study were
annealed so that their dA, or dG at 30-terminus could pair
with the analogues (Figure 2 and Supplementary Figure
S1). The steady-state Vmax and Km for the extension from
dA or dG with the N
4-modiﬁed cytidine analogues in RNA
templates were determined from the time course experiments
(Figure 5) using the template-primers. The observed values
of kinetic data for each reaction are shown in Table 2. To
compare the efﬁciency of extension from each base pair,
the frequency values of extension (fext) were deﬁned as the
ratio of catalytic efﬁciency (Vmax/Km) for each reaction.
The extension from dA paired with ho
4C and mo
4C
occurred 7-fold less efﬁciently than for the dA:U pair. The
extension frequency of dA:sc
4C pair was 78-fold lower than
dA:U pair. In contrast, the fext value of dA:rP pair was similar
to dA:U pair. The fext values of dG paired with ho
4C, mo
4C
and rP were about the same as each other and 10-fold
higher than the values of dG:U pair. The fext value of
dG:sc
4C pair was slightly lower than the other analogues
paired with dG. The extension from dG pair occurred
2945-fold less frequently than dA pair when paired with U.
The extension frequencies of dG pair were 33, 34, 376 and
7-fold lower than dA pair when paired with ho
4C, mo
4C, rP
and sc
4C, respectively. Consequently, dG pairs were
extended less frequently than dA pairs, but the extension
ratio of dG pair to dA pair was higher when paired with
these analogues. It is also notable that the lower extension
from dG may not indicate instability of the dG-analogue
pairs, because dG paired with cytidine also showed a lower
extension frequency compared to dA paired with uridine.
Incorporation of ribonucleotide analogues in
transcription by human RNA polymerase II
In this study, we have analyzed the templating properties of
N
4-cytidine analogues in RNA during reverse transcription
by HIV RT. It is important to know whether they can be
incorporated into RNA by human RNA polymerase II. This
was examined by nearest-neighbor analysis of the products
of transcription reaction using HeLa nuclear extract in the
presence of [a-
32P]GTP and the N
4-cytidine analogues.
Following transcription, the transcripts were digested to
nucleoside 30-monophosphates, which were separated by
two-dimensional TLC. Radioactive spots corresponding to
the analogues were observed when ho
4CTP, mo
4CTP and
rPTP were used in place of UTP and sc
4CTP in place of
CTP (Figure 6). From the intensities of the spots, the amount
of incorporated ho
4Cp, mo
4Cp, rPp and sc
4Cp were
calculated to be 3.6, 3.6, 12 and 12% of total nucleotides in
synthesized transcripts, respectively (Table 3). Up and Cp
derived from UTP and CTP, which were not added to the
reaction, were also detected possibly due to presence of
small amounts of the triphosphates in the extract. When
UTP and CTP were added at 20% of the concentration of
rPTP and sc
4CTP, the spots of the rPp and sc
4Cp were
detected, and expected products were formed (Supplementary
Figure S5).
DISCUSSION
In this study, we have investigated the templating properties
of ribonucleotide analogues, ho
4C, mo
4C, m
4C, sc
4C and rP
in reverse transcription for an assessment of their mutagenic
potentials for the development of antiviral drugs. Ribonu-
cleotides might be more suitable for this purpose than
deoxyribonuclotides because they are less likely to disturb
the host genetic machinery. In the present study, three
N
4-oxy, one N
4-amino and one N
4-alkylcytidine derivatives
were examined. N
4-modiﬁed cytidine analogues contain the
most potent nucleoside analogue mutagens (27,38). Results
of the sequencing analysis of cDNA products indicated that
substitution of U by ho
4C, mo
4C, rP and sc
4C directs the
incorporation of both dA and dG, suggesting their ability to
induce U-to-C mutations.
N
4-oxycytidines exist preferentially as the imino tautomer
(ratio 9:1) (22–24,28,29,39–42), which results in base pairing
with dA. As expected, rP, ho
4C and mo
4C preferred the
incorporation of dA. However, the ratio of dG to dA opposite
ho
4C and mo
4C was higher than expected from their base
pairing ability.
In order to examine the mechanism of the incorporation
further, we analyzed steady-state kinetics for insertion
opposite each analogue and extension from dA or dG paired
with each analogue. We found that dAMP insertion opposite
ho
4C and mo
4C was less efﬁcient than opposite U, while
dGMP was incorporated in a similar efﬁciency opposite
ho
4C, mo
4C and U. Thus, the incorporation of dGMP/
dAMP opposite the analogues increased. In contrast, an
increase in the insertion of dGMP with unchanged incor-
poration of dAMP caused the increase in the dGMP/dAMP
opposite rP. The decrease in the insertion of dATP opposite
ho
4C and mo
4C can be explained by the fact that the
N
4-hydroxy or N
4-methoxy group prefers the syn confor-
mation, which interferes with hydrogen bonding in a Watson–
Crick base pair (40–42). On the other hand, the insertion
of dATP opposite rP and U was of the same order and the
Table 1. Steady-state kinetics data for insertion opposite cytidine analogues,
ho
4C, mo
4C, rP and sc
4C in RNA templates by HIV RT
T:P Km (mM) Vmax,rel
(%/s)
(· 10
 2)
Vmax,rel/Km fins
U:dA 2.5 ± 0.5 15 ± 2 6.3(± 1.4) · 10
 2 1
U:dG 59 ± 17 3.1 ± 0.3 5.4(± 1.0) · 10
 4 8.8(± 1.6) · 10
 3
U:dC 2038 ± 575 6.0 ± 1.3 3.1(± 1.0) · 10
 5 5.0(± 1.3) · 10
 4
U:dT 2680 ± 381 1.8 ± 0.4 6.8(± 0.7) · 10
 6 1.1(± 0.2) · 10
 4
ho
4C:dA 70 ± 13 22 ± 1 3.2(± 0.6) · 10
 3 5.1(± 0.4) · 10
 2
ho
4C:dG 62 ± 4 11 ± 2 1.7(± 0.4) · 10
 3 2.8(± 0.5) · 10
 2
ho
4C:dC 1963 ± 1086 7.8 ± 1.7 4.5(± 1.4) · 10
 5 7.5(± 3.0) · 10
 4
ho
4C:dT 2239 ± 807 11 ± 1 5.5(± 2.9) · 10
 5 8.7(± 3.9) · 10
 4
mo
4C:dA 131 ± 15 20 ± 2 1.5(± 0.2) · 10
 3 2.6(± 1.0) · 10
 2
mo
4C:dG 158 ± 75 9.8 ± 1.7 6.9(± 2.5) · 10
 4 1.1(± 0.3) · 10
 2
mo
4C:dC 2742 ± 962 3.7 ± 0.8 1.5(± 0.8) · 10
 5 2.3(± 0.9) · 10
 4
mo
4C:dT 3486 ± 477 5.8 ± 0.3 1.7(± 0.3) · 10
 5 2.8(± 0.6) · 10
 4
rP:dA 2.4 ± 0.2 26 ± 7 1.1(± 0.3) · 10
 1 1.9 ± 0.7
rP:dG 15 ± 2 14 ± 2 9.7(± 3.2) · 10
 3 1.6(± 0.6) · 10
 1
rP:dC 1870 ± 296 7.6 ± 0.9 4.2(± 1.2) · 10
 5 7.0(± 2.5) · 10
 4
rP:dT 1730 ± 457 3.7 ± 0.3 2.3(± 0.8) · 10
 5 3.7(± 1.2) · 10
 4
sc
4C:dA 234 ± 21 5.3 ± 1.3 2.3(± 0.7) · 10
 4 3.9(± 2.0) · 10
 3
sc
4C:dG 5.0 ± 0.7 3.1 ± 0.0 6.3(± 0.8) · 10
 3 1.0(± 0.3) · 10
 1
C:dG 1.7 ± 0.9 6.0 ± 0.8 3.8(± 1.2) · 10
 2
No extended products from sc
4C:dC and sc
4C:dT.
6444 Nucleic Acids Research, 2006, Vol. 34, No. 22ratio of dATP and dGTP inserted opposite rP was similar
to the ratio of its imino and amino tautomers (29). This
suggests that the imino and amino tautomers of rP behave
like natural U and C, because the N
4-hydroxyl group is
constrained in an anti-form away from the hydrogen bonding
face enabling hydrogen bonding by Watson–Crick base
pairing (43,44).
The extension frequencies from dA and dG paired with
N
4-oxy-cytidine analogues also show an interesting feature.
The extension frequency from dA:rP pair was 10-fold higher
than those from dA:ho
4C pair and dA:mo
4C pair, while the
frequencies from dG were identical. This is clearly due to
the preference for the syn-conﬁguration in the imino-forms
of ho
4C and mo
4C. It interferes with Watson–Crick pairing
with dA, but can pair with dG through the wobble-type con-
formation (45), which possibly changes to Watson–Crick
base pairing with a transition to the amino-form (46) after
its incorporation. From the latter base pair the chain could
extend efﬁciently. It should also be noted that the G/A ratio
of incorporation opposite analogues should depend upon the
Figure 5. Extension from nucleotides incorparated opposite cytidine analogues. p: primer only.
Nucleic Acids Research, 2006, Vol. 34, No. 22 6445dGTP/dATP ratio, but the extension from G-analogue pair
should depend solely upon the concentration of dGTP,
which will be incorporated opposite C next to the analogue.
The concentrations of all the dNTPs used in our experiments
of cDNA synthesis were higher than the Km for dG paired
with the analogues, but lower than the Km for dG mismatched
with uridine. Therefore, the dNTP concentration would be
sufﬁcient to extend from dG paired with the analogues, but
not uridine. Thus this selection step may efﬁciently compli-
ment the low ﬁdelity insertion step to avoid the errors in
cDNA synthesis from normal RNA, but it may not in the
synthesis from RNA containing analogues.
N
4-aminocytidine derivatives are also highly mutagenic
analogues with tautomeric ambiguity in their structures
(25,47). N
4-aminocytidine derivatives exist preferentially in
the amino tautomeric form (28,48), and our results are consis-
tent with this. We examined here sc
4C, an N
4-aminocytidine
derivative, which directs the incorporation of both dGMP and
dAMP but with a preference for dGMP. N
4-alkylated cytid-
ine, N
4-methylcytidine behaves as cytidine only. Although
we need to examine other conditions, N
4-modiﬁcation
without tautomerism does not seem to affect incorporation.
These facts suggested that a cytidine analogue that has
equal amino and imino tautomers and prefers the anti
conformation, were such an analogue available, would be
more mutagenic and a useful nucleotide as an antiviral drug
as we have described.
Table 2. Steady-state kinetics data for extension from dA or dG paired with
a cytidine analogue, ho
4C, mo
4C, rP or sc
4C by HIV RT
T:P Km (mM) Vmax,rel
(%/s)
(·10
 2)
Vmax,rel/Km fext
U:dA 0.17 ± 0.04 4.3 ± 0.2 2.6(± 0.4) · 10
 1 1
ho
4C:dA 2.6 ± 0.2 8.5 ± 0.1 3.3(± 0.2) · 10
 2 1.3(± 0.3) · 10
 1
mo
4C:dA 2.9 ± 1.1 10 ± 2 3.7(± 0.8) · 10
 2 1.5(± 0.5) · 10
 1
rP:dA 0.18 ± 0.04 6.7 ± 0.1 3.8(± 0.7) · 10
 1 1.5 ± 0.5
sc
4C:dA 4.6 ± 1.8 1.5 ± 0.2 3.5(± 1.2) · 10
 3 1.3(± 0.3) · 10
 2
U:dG 1600 ± 494 14 ± 3 9.2(± 1.9) · 10
 5 3.6(± 0.9) · 10
 4
ho
4C:dG 166 ± 7 17 ± 1 1.0(± 0.1) · 10
 3 3.8(± 0.8) · 10
 3
mo
4C:dG 162 ± 29 18 ± 1 1.1(± 0.1) · 10
 3 4.3(± 0.8) · 10
 3
rP:dG 149 ± 6 15 ± 1 1.0(± 0.1) · 10
 3 3.9(± 1.0) · 10
 3
sc
4C:dG 48 ± 15 2.6 ± 0.04 5.9(± 2.1) · 10
 4 2.4(± 1.3) · 10
 3
C:dG 72 ± 14 10 ± 1 1.5(± 0.4) · 10
 3
Figure 6. Incorporation of cytidine analogues with HeLa nuclear extract. The transcripts were analyzed by denaturing 5% polyacrylamide gel electrophoresis.
Above each lane, rNTP added to the extract are recorded. Molar ratios of ATP:(
32P-)GTP:CTP:UTP:C*TP is 1:0.04:1:1:1 if present (A). Two-dimensional
cellulose TLC for nearest-neighbor analyses of the transcripts (B). In the transcription, the CTP analogues, ho
4CTP, mo
4CTP and rPTP, respectively, were added
in place of UTP, while sc
4CTP was added in place of CTP.
6446 Nucleic Acids Research, 2006, Vol. 34, No. 22The ribonucleotide analogues need to be incorporated into
RNA by the host RNA polymerase II to induce mutations
into the retroviral genome. One option would be to use the
nucleoside analogues and then to rely on the host cellular
processes to convert the nucleosides to the active triphosphate
substrates, though at this stage we do not know whether the
nucleosides are substrates for cellular kinases. We examined
the incorporation of the analogue triphosphates by human
RNA polymerase II; the results suggest that ho
4CTP,
mo
4CTP and rPTP are incorporated in place of UTP, and
sc
4CTP is incorporated in place of CTP. rPTP and sc
4CTP
are more efﬁciently incorporated into RNA than ho
4CTP
and mo
4CTP. It should be noted that whilst the experiments
described here use relatively high concentrations of analogue
triphosphates, in a therapeutic sense it would be feasible to
use lower concentrations. This is because a relatively low
mutation frequency will lead to error catastrophe with the
virus, and because the mutations can build up over successive
rounds of replication.
We have examined a series of potentially mutagenic
cytidine analogues with the view that these might induce
error catastrophe if incorporated into viral genomic RNA.
The data supports the view that certain of the analogues
examined induce mutations both by misincorporation into
RNA and by reverse transcription. From the results men-
tioned above, these analogues except for m
4C may induce
mutations in the retroviral genome if present as triphosphates.
At present the analogues described here have not been
assayed as antiviral agents. To apply the nucleosides as
antiretroviral drugs, the nucleosides need to pass through
the cell membrane, and to be phosphorylated by cellular
kinases for generation the active triphosphates. To bypass
the kinase step, liposomal-based drug delivery methods
may be available to transport the 50-triphosphate into the
cell (49,50). Phosphorylated pronucleotides (masked phos-
phate analogues) may also useful (51,52). By using these
methods, we could deliver the phosphorylated analogues
into the cell; induce mutations in retroviruses, leading to
error catastrophe. Intracellular pyrimidine concentrations
are generally much lower than purine concentrations (53)
the latter are implicated in important cellular processes,
such as metabolic process and signaling besides DNA and
RNA synthesis. Thus, use of mutagenic pyrimidine analogues
might be more effective, and result in less adverse cellular
effects. Additionally, it will be possible to improve the
therapeutic efﬁcacy by combinations of mutagenic nucleoside
and antiviral inhibitor (54–57). Further work would be
required to determine the antiviral efﬁcacy of these
analogues, but we have provided evidence to support the
fact that if incorporated into viral RNA the analogues could
lead to lethal mutagenesis.
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